| Name | Title | Contact Details |
|---|---|---|
Wendy Vargas |
VP Global CO Project Leader Head, Rare Disease, Rare Blood Disorders, Oncology | Profile |
Sophie Forge |
VP - Global Head of Digital R&D Pipeline and Project analytics | Profile |
Andrey Malyy |
Global Head of Information Technology Solutions, Innovation, CX and Mobile | Profile |
Arnaud Robert |
Executive Vice President and Chief Digital Officer | Profile |
Michael Shanno |
Head of Digital and Information Technology | Profile |
CRB is a Oreland, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OrphoMed is a San Francisco based clinical stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles. The company is leveraging its proprietary dimer platform technology to address the issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders. OrphoMed dimers are protected by composition of matter and method of use patents.
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.
III International is a company that offers purpose-built, Proactive Wellness products designed to create demonstrable results through maximizing bioavailability and cellular absorption. Their philosophy extends beyond their products and encompasses the...
Amador Bioscience, a leading partner for successful new drug development, provides global-standard translational sciences and clinical pharmacology services to clients ranging from cutting-edge biotech start-ups to multinational pharmaceutical companies. Founded in 2018 and supported by prominent institutional investors, Amador Bioscience operates in multiple sites, Pleasanton, CA, Ann Arbor, MI, Germantown, MD, Richmond, VA, Hangzhou and Shanghai, China, and Limburg.